• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.

作者信息

El Rassy Elie, Assi Tarek, El Karak Fadi, Ghosn Marwan, Kattan Joseph

机构信息

Department of Oncology, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.

Department of Oncology, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.

出版信息

Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):e26-e28. doi: 10.1016/j.clinre.2016.11.012. Epub 2017 Feb 17.

DOI:10.1016/j.clinre.2016.11.012
PMID:28215539
Abstract
摘要

相似文献

1
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.在FOLFIRINOX方案治疗失败后，白蛋白结合型紫杉醇联合吉西他滨的方案能否挽救转移性胰腺腺癌？一项单中心回顾性分析。
Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):e26-e28. doi: 10.1016/j.clinre.2016.11.012. Epub 2017 Feb 17.
2
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?白蛋白结合型紫杉醇联合吉西他滨或 FOLFIRINOX 作为不可切除的胰腺腺癌一线治疗方案：顺序重要吗？
BMC Cancer. 2019 Jan 8;19(1):28. doi: 10.1186/s12885-018-5240-6.
3
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.转移性胰腺癌 FolFOX 方案治疗失败后吉西他滨联合 Nab-紫杉醇持续缓解：一种有效新策略的报告。
Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):e23-6. doi: 10.1016/j.clinre.2014.01.005. Epub 2014 Feb 18.
4
Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.转移性胰腺癌治疗结果的改善：一项真实世界数据分析
In Vivo. 2019 Jan-Feb;33(1):271-276. doi: 10.21873/invivo.11471.
5
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.在一名转移性胰腺腺癌患者中，FOLFIRINOX方案治疗失败后，使用纳米白蛋白结合型紫杉醇和吉西他滨成功治疗。
Onkologie. 2013;36(12):763-5. doi: 10.1159/000356811. Epub 2013 Nov 20.
6
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.转移性胰腺腺癌一线治疗方案的困境
World J Gastroenterol. 2016 Dec 14;22(46):10124-10130. doi: 10.3748/wjg.v22.i46.10124.
7
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.5-氟尿嘧啶/亚叶酸钙联合伊立替康和奥沙利铂（FOLFIRINOX）作为转移性胰腺腺癌二线化疗。
Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.
8
[FOLFIRINOX, nab-paclitaxel + gemcitabine].[FOLFIRINOX方案、纳米白蛋白紫杉醇+吉西他滨]
Nihon Rinsho. 2015 Mar;73 Suppl 3:405-8.
9
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
10
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.纳武利尤单抗联合伊匹木单抗治疗晚期肝癌的疗效和安全性：一项多中心回顾性研究
Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):295-301. doi: 10.1016/j.clinre.2019.08.009. Epub 2019 Oct 10.

引用本文的文献

1
Consensus, debate, and prospective on pancreatic cancer treatments.胰腺癌治疗的共识、争议与展望。
J Hematol Oncol. 2024 Oct 10;17(1):92. doi: 10.1186/s13045-024-01613-x.
2
Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.LDE225联合吉西他滨和纳米白蛋白结合型紫杉醇治疗转移性胰腺癌的I/II期研究
Cancers (Basel). 2021 Sep 28;13(19):4869. doi: 10.3390/cancers13194869.
3
Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer.
晚期胰腺癌一线和二线姑息化疗的真实世界证据。
World J Clin Oncol. 2021 Sep 24;12(9):787-799. doi: 10.5306/wjco.v12.i9.787.
4
Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.晚期胰腺癌中FOLFIRINOX方案后基于吉西他滨的化疗的系统评价和荟萃分析。
Ther Adv Med Oncol. 2020 Feb 28;12:1758835920905408. doi: 10.1177/1758835920905408. eCollection 2020.
5
Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients.经动脉灌注化疗与孤立性腹腔动脉灌注化疗治疗晚期胰腺癌的回顾性队列研究：454 例患者分析
J Cancer Res Clin Oncol. 2019 Nov;145(11):2855-2862. doi: 10.1007/s00432-019-03019-6. Epub 2019 Sep 10.
6
Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.聚焦脂质体伊立替康治疗转移性胰腺癌：患者选择与展望
Onco Targets Ther. 2019 Feb 21;12:1455-1463. doi: 10.2147/OTT.S167590. eCollection 2019.
7
Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.对在FOLFIRINOX方案治疗中出现疾病进展的转移性胰腺腺癌患者，基于吉西他滨的化疗的疗效和安全性的回顾性分析。
J Gastrointest Oncol. 2018 Oct;9(5):806-819. doi: 10.21037/jgo.2018.06.08.
8
Clinical Trials in Pancreatic Cancer: A Long Slog.胰腺癌临床试验：漫漫征途。
Oncologist. 2017 Dec;22(12):1424-1426. doi: 10.1634/theoncologist.2017-0453. Epub 2017 Oct 5.
9
Current Standards of Chemotherapy for Pancreatic Cancer.当前胰腺癌化疗标准。
Clin Ther. 2017 Nov;39(11):2125-2134. doi: 10.1016/j.clinthera.2017.08.015. Epub 2017 Sep 19.